Article
Novo inks $1.3B deal for monthly — or even quarterly — GLP-1 shots
Novo will pay up to $1.3 billion to license technology from Sweden's Nanexa that could significantly change how patients take popular obesity drugs. Under the terms of the deal announced Friday, the Ozempic maker will help develop Nanexa's PharmaShell drug-delivery system — hopefully cutting the number of injections people need to just once a month or even once a quarter. Novo exec Brian Stidsen Vandahl explains, "As patient populations become increasingly diverse, we see value in pursuing different approaches that can help address varying needs, preferences and treatment experiences."
Novo Nordisk is making a major bet on technology that could dramatically reduce how often patients need to inject obesity and diabetes medicines. The Danish pharmaceutical giant has entered a licensing and development agreement with Sweden’s Nanexa...
